AKT1 and hepatocellular carcinoma: The combination of APS with LY294002 further enhanced apoptosis (apoptosis rate of 58.16%), indicating that APS suppresses hepatoma cell proliferation via the dual actions of autophagy activation and Akt pathway inhibition, thereby offering a potential therapeutic target for liver cancer [57].